Expert Guidance for Your Treatment Transition
Online Prescription Process for Moving From Wegovy to Mounjaro
Moving from Wegovy to Mounjaro requires careful clinical consideration of your individual response, medical history, and treatment goals. Our online prescription service streamlines this transition process through a comprehensive 3-minute clinical assessment that evaluates your current Wegovy experience, any side effects encountered, and your suitability for tirzepatide therapy. Licensed UK prescribers review each case individually, considering factors such as your weight loss progress, gastrointestinal tolerance, and any contraindications specific to dual-hormone therapy. The assessment covers your BMI history, current medications, and reasons for considering the switch from semaglutide to tirzepatide.
Unlike traditional GP referrals that can take weeks, our online process typically provides prescriber decisions within 3 working days, with express 24-hour review available for treatment transitions. This rapid turnaround ensures minimal disruption to your weight management therapy when moving from Wegovy to Mounjaro. Our GPhC-registered pharmacy (#9012878) maintains full clinical records throughout your transition, ensuring continuity of care and appropriate dose escalation protocols for your new prescription-only medicine.
Pricing and Value When Switching From Wegovy to Mounjaro
When moving from Wegovy to Mounjaro, understanding the cost implications helps you make informed decisions about your weight management investment. Mounjaro starts at £79.99 for the 2.5mg starter dose with discount code FIRST40 for new customers, whilst returning patients use code DOSE25 at checkout. The tirzepatide dose escalation follows a different schedule than semaglutide - beginning with 2.5mg for 4 weeks, then 5mg, 10mg, and maintenance doses up to 15mg weekly. Our Getting Started bundles provide convenient progression packs, such as the Intro Duo (2.5mg & 5mg) for £169.99, ensuring seamless transition without treatment gaps.
For patients moving from Wegovy to Mounjaro, we offer Consistency bundles for those who need to stabilise on specific doses during transition. The Consistency 2.5mg bundle provides two starter pens for £139.99, allowing extended time at the initial dose if switching causes initial sensitivity. Our Ultimate Maintenance Trio offers three 15mg pens for continued therapy once your optimal dose is established. All pricing includes next-day cold-chain delivery and full prescriber support throughout your transition period.
Clinical Evidence Supporting Treatment Transitions
Research supporting transitions when moving from Wegovy to Mounjaro centres on the different mechanisms of action between semaglutide and tirzepatide. The SURPASS clinical trial programme demonstrated tirzepatide's dual GIP and GLP-1 receptor agonism, whilst Wegovy's STEP trials focused on GLP-1-only activity (Wilding et al., NEJM, 2021). Some patients may experience different efficacy profiles or side effect tolerability between these mechanisms, making supervised transitions clinically appropriate.
Clinical evidence suggests that patients moving from Wegovy to Mounjaro may experience different gastrointestinal side effect patterns, appetite regulation, or weight loss trajectories. However, individual responses vary significantly, and transitions should always be conducted under prescriber supervision with appropriate dose escalation protocols for the new prescription-only medicine.
How Mounjaro Differs From Wegovy in Mechanism
Understanding the mechanistic differences is crucial when moving from Wegovy to Mounjaro, as tirzepatide offers dual-hormone activity compared to semaglutide's single-target approach. Mounjaro activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, potentially providing enhanced appetite suppression and glucose regulation compared to Wegovy's GLP-1-only mechanism. This dual agonism may explain why some patients experience different efficacy or tolerability profiles when transitioning between treatments. The GIP component additionally influences fat metabolism and insulin sensitivity, offering a broader metabolic impact than traditional GLP-1 therapies. Both treatments must be used alongside a reduced-calorie diet and increased physical activity as part of comprehensive weight management programmes.
Streamlined Ordering Process for Treatment Switches
Our ordering process for moving from Wegovy to Mounjaro begins with a detailed clinical assessment covering your semaglutide experience, including duration of treatment, highest dose achieved, weight loss response, and any adverse effects encountered. The assessment evaluates your suitability for tirzepatide therapy, considering contraindications and drug interactions specific to dual-hormone agonists. Licensed prescribers review your case within 3 working days (express 24-hour option available), ensuring appropriate transition protocols and dose escalation schedules. Upon approval, your Mounjaro prescription is dispatched via next-day cold-chain delivery, maintaining the temperature-controlled conditions essential for peptide stability. Full patient information leaflets and injection guidance accompany each order, supporting confident self-administration during your treatment transition.
Storage and Practical Considerations for Your Transition
Storage requirements differ when moving from Wegovy to Mounjaro, with important implications for treatment continuity during your transition period. Mounjaro requires refrigeration at 2-8°C before first use, similar to Wegovy, but offers only 21 days at room temperature once removed from cold storage, compared to Wegovy's 6-week room temperature stability. Both treatments use pen injectors, though Mounjaro's KwikPen differs from Wegovy's FlexTouch system, requiring familiarisation with new injection techniques. The dose escalation schedule for tirzepatide starts lower than semaglutide maintenance doses, beginning at 2.5mg weekly regardless of your previous Wegovy dose. Plan your transition timing to ensure refrigeration access and allow adequate adaptation to the new injection system and dosing schedule. Store both treatments in their original cartons to protect from light, and never freeze or shake the pens during storage.
Transition Timeline and Clinical Monitoring
Successfully moving from Wegovy to Mounjaro requires structured transition planning with appropriate washout periods and clinical monitoring throughout the switch. Most prescribers recommend stopping semaglutide and beginning tirzepatide after a brief washout period, typically 1-2 weeks, to minimise overlapping GLP-1 effects and reduce gastrointestinal side effect risks. The tirzepatide dose escalation begins at 2.5mg weekly regardless of your previous Wegovy dose, as the dual-hormone mechanism requires separate tolerance assessment. Clinical monitoring should include weight, gastrointestinal symptoms, and glucose levels if diabetic, with regular prescriber contact during the first 8 weeks of transition.
Your transition success when moving from Wegovy to Mounjaro depends on realistic expectations and consistent clinical support throughout the dose escalation period. Some patients notice different appetite effects, nausea patterns, or injection site reactions compared to semaglutide, requiring individualised management strategies. Our clinical team provides ongoing support through your transition, adjusting escalation timing if needed and ensuring optimal outcomes with your new prescription-only medicine regimen.
Complete Your Transition With Expert Support
Ready to begin moving from Wegovy to Mounjaro with professional clinical oversight? Our comprehensive transition service includes pre-switch assessment, prescribed dose escalation protocols, and ongoing monitoring throughout your tirzepatide therapy. New customers apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 for optimal pricing on their treatment switch. Visit https://everydaymeds.co.uk/collections/wegovy to complete your 3-minute clinical assessment and begin your supervised transition with confidence. Our GPhC-registered pharmacy (#9012878) ensures full regulatory compliance and clinical safety throughout your weight management journey. Don't navigate treatment transitions alone - let our expert prescribers guide your move from semaglutide to tirzepatide therapy with personalised clinical care.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
